Could a blood test help more lung cancer patients get drugs that are targeted to the genetic weaknesses of their tumors?

Yes, according to summary results of a 282-patient clinical trial being made available Wednesday. The result is a boon for Guardant Health, the San Francisco-based startup that sells the test, Guardant360, which is a “liquid biopsy” that works by detecting fragments of DNA in the bloodstream. The full study will be presented in full at the annual meeting of the American Association for Cancer Research in early April.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy